Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent chemoradiotherapy with adjuvant metronomic temozolomide for high-grade gliomas
ChiCTR2400086602Phase 3Not yet recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioma and glioblastoma (GBM) (2 arms), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoint: Grade 3-4 hematological toxicity. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
temozolomide
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2400086602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086602.